Skip to Main Content

File this under “one step forward, two steps back.”

Just one week after Pfizer hoped to resume full production at a manufacturing plant with long-standing quality control problems, the drug maker has had to hit the pause button on some activities due to “additional maintenance” that needs to be performed, according to a company spokesman.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED